Characterization of the role of the photosensitizer, deuteporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model

Yu,Xinzhe; Li,Hengchao; Fu,Deliang; Jin,Chen; Li,Ji

doi:10.3892/ol.2015.3441

Characterization of the role of the photosensitizer, deuteporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model

Authors:
- Xinzhe Yu
- Hengchao Li
- Deliang Fu
- Chen Jin
- Ji Li
View Affiliations

Affiliations: Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: June 30, 2015 https://doi.org/10.3892/ol.2015.3441
Pages: 1430-1436

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, the use of photosensitizers as tracer agents to detect lymphatic metastases is a developing area of study in the field of pancreatic cancer treatment. In the present study, deuteporfin, a novel photosensitizer, was used as a tracer agent to detect lymphatic metastases in a pancreatic cancer xenograft model. The biodistribution and pharmacokinetics of deuteporfin, following intravenous administration and injection of deuteporfin into the left rear footpad, were investigated in Sprague‑Dawley rats. The increased difference in deuteporfin concentration between the cancerous and normal tissues was directly observed through the application of a Wood’s lamp. In addition, the highly lymphatic BxPC‑3‑LN5 human metastatic pancreatic cancer cell line was generated from BxPC‑3 cells using a continuous screening and seeding method in vivo. A xenograft model of the BxPC‑3‑LN5 human pancreatic cancer cell line transplanted into the left rear footpad of nude mice, was established. The effects of deuteporfin as a tracer agent in the detection of lymphatic metastases were then characterized in the pancreatic cancer xenograft model. Following intravenous administration, deuteporfin was rapidly enriched in the pancreas and popliteal fossa lymph nodes compared with that of the left rear footpad administration group. In addition, deuteporfin appeared to be selectively enriched in the cancerous pancreatic lymph nodes of the pancreatic cancer xenograft model. These results indicated that deuteporfin may be developed as a novel photosensitizer tracer agent for the detection of lymphatic metastases in pancreatic cancer. The advantages of deuteporfin are that it has a selective tumor‑targeting effect due to high tissue uptake, and that it may be administered intravenously and is therefore suitable for surgery.

View Figures

View References

1	Saleem A, Jackson A, Mukherjee S, Stones N, Crosby T, Tait D and Price PACORRN UK Pancreatic Radiotherapy Group: Radiotherapy in the management of unresectable locally advanced pancreatic cancer: A survey of the current UK practice of clinical oncologists. Clin Oncol (R Coll Radiol). 22:257–260. 2010. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
4	Braat H, Bruno M, Kuipers EJ and Peppelenbosch MP: Pancreatic cancer: Promise for personalized medicine. Cancer Lett. 318:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chan A, Diamandis EP and Blasutig IM: Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics. 81:126–134. 2013. View Article : Google Scholar : PubMed/NCBI
6	McAllaster JD and Cohen MS: Role of the lymphatics in cancer metastasis and chemotherapy applications. Adv Drug Deliv Rev. 63:867–875. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang F, Jin C, Subedi S, Lee CL, Wang Q, Jiang Y, Li J, Di Y and Fu D: Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 38:566–579. 2012. View Article : Google Scholar : PubMed/NCBI
8	Russell M and Anzai Y: Ultrasmall superparamagnetic iron oxide enhanced MR imaging for lymph node metastases. Radiography. 13:e73–e84. 2007. View Article : Google Scholar
9	Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, Rasoul Zakavi S, Memar B, Naser Forghani M, Mehrabibahar M and Sadeghi R: Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl. 29:73–77. 2010. View Article : Google Scholar : PubMed/NCBI
10	Varghese P, Mostafa A, Abdel-Rahman AT, Akberali S, Gattuso J, Canizales A, Wells CA and Carpenter R: Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localization in early breast cancer. Eur J Surg Oncol. 33:147–152. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ogasawara Y, Yoshitomi S, Sato S and Doihara H: Clinical significance of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer. J Surg Res. 148:191–196. 2008. View Article : Google Scholar : PubMed/NCBI
12	Noh YW, Kong SH, Choi DY, et al: Near-infrared emitting polymer nanogels for efficient sentinel lymph node mapping. ACS Nano. 6:7820–7831. 2012. View Article : Google Scholar : PubMed/NCBI
13	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
14	Dolmans DE, Fukumura D and Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003. View Article : Google Scholar : PubMed/NCBI
15	Lovell JF, Liu TW, Chen J and Zheng G: Activatable photosensitizers for imaging and therapy. Chem Rev. 110:2839–2857. 2010. View Article : Google Scholar : PubMed/NCBI
16	Issa MC and Manela-Azulay M: Photodynamic therapy: A review of the literature and image documentation. An Bras Dermatol. 85:501–511. 2010.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
17	Nishioka NS: Drug, light, and oxygen: A dynamic combination in the clinic. Gastroenterology. 114:604–606. 1998. View Article : Google Scholar : PubMed/NCBI
18	Fan BG and Andrén-Sandberg A: Photodynamic therapy for pancreatic cancer. Pancreas. 34:385–389. 2007. View Article : Google Scholar : PubMed/NCBI
19	Brown SB, Brown EA and Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5:497–508. 2004. View Article : Google Scholar : PubMed/NCBI
20	Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, Pogue BW and Hasan T: Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem Rev. 110:2795–2838. 2010. View Article : Google Scholar : PubMed/NCBI
21	Abd-Elgaliel WR, Cruz-Monserrate Z, Wang H, Logsdon CD and Tung CH: Pancreatic cancer-associated Cathepsin E as a drug activator. J Control Release. 167:221–227. 2013. View Article : Google Scholar : PubMed/NCBI
22	Anand S, Ortel BJ, Pereira SP, Hasan T and Maytin EV: Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett. 326:8–16. 2012. View Article : Google Scholar : PubMed/NCBI
23	Pawlik TM, Gleisner AL, Cameron JL, et al: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 141:610–618. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ni X, Yang J and Li M: Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett. 324:179–185. 2012. View Article : Google Scholar : PubMed/NCBI
25	Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 5:29–49. 1986. View Article : Google Scholar : PubMed/NCBI
26	Tamada Y, Aoki D, Nozawa S and Irimura T: Model for paraaortic lymph node metastasis produced by orthotopic implantation of ovarian carcinoma cells in athymic nude mice. Eur J Cancer. 40:158–163. 2004. View Article : Google Scholar : PubMed/NCBI
27	Schroder T, Chen IW, Sperling M, Bell RH Jr, Brackett K and Joffe SN: Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma. J Surg Oncol. 38:4–9. 1988. View Article : Google Scholar : PubMed/NCBI
28	Barrett AJ, Kennedy JC, Jones RA, Nadeau P and Pottier RH: The effect of tissue and cellular pH on the selective biodistribution of porphyrin-type photochemotherapeutic agents: A volumetric titration study. J Photochem Photobiol B. 6:309–323. 1990. View Article : Google Scholar : PubMed/NCBI
29	Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic therapy. J Natl Cancer Inst. 90:889–905. 1998. View Article : Google Scholar : PubMed/NCBI
30	Alexiades-Armenakas M: Laser-mediated photodynamic therapy. Clin Dermatol. 24:16–25. 2006. View Article : Google Scholar : PubMed/NCBI
31	Kilarski WW, Muchowicz A, Wachowska M, Mężyk-Kopeć R, Golab J, Swartz MA and Nowak-Sliwinska P: Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. Angiogenesis. 17:347–357. 2013. View Article : Google Scholar : PubMed/NCBI
32	Taylor MJ, Hoerauf A and Bockarie M: Lymphatic filariasis and onchocerciasis. Lancet. 376:1175–1185. 2010. View Article : Google Scholar : PubMed/NCBI
33	Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 296:1883–1886. 2002. View Article : Google Scholar : PubMed/NCBI
34	Wang R, Hao H, Wang G, Xie H, Xu M, Wang W, He H and Li X: Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. J Photochem Photobiol B. 90:179–186. 2008. View Article : Google Scholar : PubMed/NCBI